Business Context and Reporting Period
Company: Adherex Technologies Inc. (Note: Input metadata referenced "Fennec Pharmaceuticals," but the filing text identifies the registrant as Adherex Technologies Inc.)
Period: Quarterly period ended March 31, 2007.
Status: Development-stage biopharmaceutical company focused on cancer therapeutics. This is the first Form 10-Q filed after the company ceased to be a "foreign private issuer" and became fully subject to U.S. Exchange Act reporting requirements. The company changed its primary basis of accounting from Canadian GAAP to U.S. GAAP effective January 1, 2007.
Key Financial Metrics
| Metric | Q1 2007 | Q1 2006 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(3,968,000) | $(3,177,000) |
| Loss Per Share (Basic/Diluted) | $(0.05) | $(0.07) |
| Operating Expenses | $4,115,000 | $3,307,000 |
| Cash and Cash Equivalents (End of Period) | $22,468,000 | $9,509,000 |
| Net Cash Used in Operating Activities | $(6,434,000) | $(3,213,000) |
| Net Cash Provided by Financing Activities | $23,237,000 | $27,000 |
| Working Capital | $20,689,000 | $1,200,000 |
| Accumulated Deficit | $(74,990,000) | $(71,022,000) |
Material Changes vs. Prior Period
- Liquidity Improvement: Cash and cash equivalents increased from $5.7 million (Dec 31, 2006) to $22.5 million (Mar 31, 2007), driven by a public offering completed on February 21, 2007, which generated gross proceeds of $25.0 million and net proceeds of approximately $23.2 million.
- Increased Net Loss: Net loss increased by approximately $791,000 compared to Q1 2006. This was primarily due to a $1.0 million upfront fee paid to GlaxoSmithKline (GSK) to purchase their remaining buy-back options for the product candidate eniluracil.
- Operating Cash Flow: Net cash used in operating activities more than doubled to $6.4 million, largely due to the $1.0 million GSK payment and the settlement of liabilities following the capital raise.
- Accounting Change: The company adopted U.S. GAAP, resulting in the immediate expensing of the $1.0 million license fee (under Canadian GAAP, this would have been capitalized and amortized).
Outlook, Risks, and Management Commentary
- Capital Runway: Management believes current cash resources are sufficient to satisfy anticipated capital requirements into the fourth quarter of 2008. Additional funding will be required thereafter via equity, debt, or collaborations.
- Product Pipeline:
- Eniluracil: Company now has full control over development after buying out GSK's options. Future milestones to GSK include $5.0 million upon NDA filing and up to $70.0 million based on commercial success.
- ADH-1: GSK's option to license this compound expired unexercised in October 2006. Patient enrollment for Phase Ib/II and Phase II studies was completed in late 2006.
- STS: A chemoprotectant for hearing loss; a randomized study with SIOPEL is projected to begin in the first half of 2007.
- Risks:
- Regulatory Approval: No products have received regulatory approval; significant risk of failure in clinical trials.
- Financing: No assurance that additional capital will be available on favorable terms or at all.
- Compliance Costs: Loss of foreign private issuer status will result in increased expenses to comply with U.S. securities laws (e.g., Sarbanes-Oxley, Regulation FD).
- Collaboration Dependence: Reliance on third parties for clinical trials and manufacturing; potential for delays or termination of agreements.
Investor Verification Checklist
- Capital Adequacy: Verify the burn rate against the $22.5 million cash balance to confirm the runway extends to Q4 2008 as projected.
- Eniluracil Milestones: Assess the financial impact of the potential $75 million in future milestone payments to GSK upon NDA filing and commercial success.
- Clinical Trial Progress: Monitor the commencement of the STS randomized study and the data readouts from ADH-1 combination trials.
- Dilution Risk: Review the impact of outstanding warrants (approx. 60.5 million) and stock options (approx. 5.8 million) on future share count.
- Accounting Treatment: Confirm the impact of the U.S. GAAP transition on future financial reporting, specifically regarding the expensing of in-process research and development.